Study on Ado-Trastuzumab Emtansine for Patients with HER2 Amplified or Mutant Cancers

Inclusion Criteria

• Adults aged 18 years or older.
• Have advanced solid tumor cancers confirmed by medical tests.
• For certain groups, have specific HER2 mutations in lung cancer confirmed by a certified lab.
• For other groups, have HER2 amplification confirmed by specific genetic tests or other approved methods.
• Have measurable or evaluable cancer lesions as defined by standard criteria.
• Have a performance status of 70% or higher, meaning able to carry out normal activities with some effort.
• Have a heart function of 50% or higher as measured by specific heart tests.
• Women of childbearing age must have a negative pregnancy test before joining the study.
• Agree to use effective birth control during the study and for a period after the last dose.
• Have certain blood cell counts and liver function within specified limits.
• Agree to provide written consent to participate in the study and follow its procedures.

Exclusion Criteria

• Have had certain high doses of specific chemotherapy drugs in the past.
• Have previously been treated with ado-trastuzumab emtansine.
• Have heart failure or recent severe heart problems.
• Have severe nerve damage.
• Are pregnant or breastfeeding.
• Have an allergy to any part of ado-trastuzumab emtansine.
• Have a history of certain lung diseases.